Review Services
Gene Therapy Ready Site Network
Advarra’s Gene Therapy Ready (GTR) Site Network includes over 1,500 vetted sites worldwide, prepared for clinical trials involving genetic engineering. These sites support the acceleration of cell and gene therapy trials by ensuring compliance, safety, and faster study startup times. Sites can join the network at no cost to demonstrate their readiness and attract more advanced clinical trials.
Key Benefits
- Largest global network of NIH-registered sites
- Faster study startup
- No cost to join
- IBC review in ≤10 business days
GTR Advantages
Faster Clinical Trial Startup
Network sites complete study startup 5-6 weeks faster than non-network sites, and 8-12 weeks faster than sites using a local institutional biosafety committee (IBC).
Comprehensive Site Support
Advarra works with network sites to ensure compliance with NIH and biosafety standards, reducing risks and making them more attractive to sponsors.
No Cost and No Commitment
Joining the network is free, with no obligations beyond maintaining biosafety compliance. This gives sites a competitive edge without added costs.
Complementary NIH Registration
Sites receive complimentary National Institutes of Health (NIH) registration when Advarra serves as the IBC of record. This simplifies the startup process, helps ensure compliance with NIH Guidelines.
Demonstrated Site Expertise
Membership demonstrates a site’s expertise and readiness to safely conduct trials involving genetically engineered therapies and vaccines. This attracts sponsors and proves site capabilities in handling complex gene therapy studies. This helps attract more industry-sponsored trials and proves the site’s commitment to biosafety best practices.
Turnaround Times
Sites in Advarra’s GTR Network are pre-registered with NIH to conduct research according to NIH Guidelines, have an existing IBC, and prior experience with human gene transfer studies. This results in significantly shorter review and approval times. When Advarra serves as both the central institutional review board (IRB) and IBC, network sites can often be approved in just a few days – dramatically faster than sites outside the network.
Sites
Is your site ready to take part in cutting-edge gene therapy and mRNA-based clinical trials?
Sponsors
Need access to 1,500+ gene therapy sites ready to start research?
